GPC3-CAR and IL15 plus IL21 / Baylor College of Medicine - LARVOL DELTA

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells (clinicaltrials.gov) - P1 | N=21 | Recruiting | Sponsor: Baylor College of Medicine | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatoblastoma • Hepatocellular Cancer • Liposarcoma • Nephrology • Oncology • Rhabdoid Tumor • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Wilms Tumor

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Baylor College of Medicine | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liposarcoma • Liver Cancer • Nephrology • Oncology • Pediatrics • Rhabdoid Tumor • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Wilms Tumor • GPC3

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells (clinicaltrials.gov) - P1 | N=21 | Not yet recruiting | Sponsor: Baylor College of Medicine

CAR T-Cell Therapy • New P1 trial • Gastrointestinal Cancer • Hepatoblastoma • Hepatocellular Cancer • Hepatology • Liposarcoma • Nephrology • Oncology • Rhabdoid Tumor • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Wilms Tumor

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Baylor College of Medicine; Trial completion date: Jul 2040 ➔ Jul 2041; Initiation date: Jul 2022 ➔ Jul 2023; Trial primary completion date: Aug 2025 ➔ Aug 2026

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liposarcoma • Liver Cancer • Nephrology • Oncology • Pediatrics • Rhabdoid Tumor • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Wilms Tumor • GPC3

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Baylor College of Medicine

Clinical • New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liposarcoma • Liver Cancer • Nephrology • Oncology • Pediatrics • Rhabdoid Tumor • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Wilms Tumor